RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy

Citations of this article
Mendeley users who have this article in their library.


BACKGROUND: The tetraspanin CD63 is a highly N-glycosylated protein that is known to regulate cancer malignancy. However, the contribution of glycosylation of CD63 to cancer malignancy remains unclear. Previously, we reported that ribophorin II (RPN2), which is part of an N-oligosaccharyle transferase complex, is responsible for drug resistance in breast cancer cells. In this study, we demonstrate that cancer malignancy associated with the glycosylation of CD63 is regulated by RPN2.<br /><br />RESULTS: Inhibition of RPN2 expression led to a reduction in CD63 glycosylation. In addition, the localization of CD63 was deregulated by knockdown of RPN2. Interestingly, multidrug resistance protein 1 (MDR1) localization was displaced from the cell surface in CD63-silenced cells. CD63 silencing reduced the chemoresistance and invasion ability of malignant breast cancer cells. Furthermore, the enrichment of CD63/MDR1-double positive cells was associated with lymph node metastasis. Taken together, these results indicated that high glycosylation of CD63 by RPN2 is implicated in clinical outcomes in breast cancer patients.<br /><br />CONCLUSIONS: These findings describe a novel and important function of RPN2-mediated CD63 glycosylation, which regulates MDR1 localization and cancer malignancy, including drug resistance and invasion.




Tominaga, N., Hagiwara, K., Kosaka, N., Honma, K., Nakagama, H., & Ochiya, T. (2014). RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy. Molecular Cancer, 13(1). https://doi.org/10.1186/1476-4598-13-134

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free